Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
Part of paid clinical trials in Pittsburgh, Pennsylvania.
- Sponsor
- Paul Szabolcs
- Study ID
- NCT01852370
- Phase
- PHASE1/PHASE2
- Status
- Enrolling By Invitation
Conditions
- Chronic Granulomatous Disease (CGD)
- Common Variable Immune Deficiency (CVID)
- Hyper IgE Syndromes
- Hyper IgM Deficiencies
- Immunodeficiency With Predominant T-cell Defect, Unspecified
- Mendelian Susceptibility to Mycobacterial Disease
- Severe Chronic Neutropenia
- Severe Combined Immunodeficiency (SCID)
- Wiskott-Aldrich Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - 45 Years
- Healthy Volunteers
- Not accepted
Interventions
- CD3/CD19 negative allogeneic hematopoietic stem cells — BIOLOGICALNegative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
Study Details
The purpose of this study is to determine whether bilateral orthotopic lung transplantation (BOLT) followed by cadaveric partially-matched hematopoietic stem cell transplantation (HSCT) is safe and effective for patients aged 5-45 years with primary immunodeficiency (PID) and end-stage lung disease.
Key Dates
- Start date
- Jun 20, 2013
- Status verified
- Dec 2025
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2027
Study Design
- Enrollment
- 16 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: BOLT+BMTAll patients will receive a double lung transplant followed by a hematopoietic stem cell transplant. The lungs and stem cells are from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
Primary Outcome Measure
Safety: Death [ Time Frame: Up to 2 years post stem cell transplant ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania | 15224 | - |
Find similar trials in Pittsburgh, PA
By research site
Related Studies
- Natural History Study of SCID DisordersEnrolling By Invitation · National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama
- Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous DiseaseRecruiting · Ensoma · Montgomery, Alabama
- Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)PHASE2 · Recruiting · Paul Szabolcs · Pittsburgh, Pennsylvania
- Evaluation of Patients With Immune Function AbnormalitiesRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland